Directs federal health officials to use genetics to help prevent harmful drug reactions. It orders an update to the national plan on adverse drug events, sets up a federal steering committee to include pharmacogenomics in prevention efforts, and requires a report to Congress within 180 days.

Requires clear, evidence-based guidance for doctors, pharmacists, nurses, and other health workers on when and how to use pharmacogenomic testing. It also pushes improvements to electronic health records so genetic information and safety alerts show up at prescribing, upgrades FDA’s adverse event reporting system to accept EHR and patient‑friendly reports, and calls for time‑limited reports to Congress and the Comptroller General on progress and challenges.